Efficacy of trabectedin in metastatic solitary fibrous tumor

19Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Solitary fibrous tumor is a rare tumor type and has an unpredictable course. Local recurrence rate varies between 9 and 19%, and rate of metastatic involvement between 0 and 36 %. It is characterized by a typical architecture and immuno-histochemistry tests. The most important prognostic factor is the complete resection of primary tumor. Treatment of recurrences is not clearly established. If a solitary fibrous tumor is too advanced to allow surgical resection, radiotherapy and chemotherapy may be used. The most often used drugs are doxorubicine and\or ifosfamide. We report the case of man with metastatic solitary fibrous tumor treated with trabectedin, administered at a dose of 1.5 mg/m2 every 3 weeks. After 3 cycles, metastases had significantly decreased. Recurrence of the disease was demonstrated 8 months after the start of trabectedin. This case shows that trabectedin is a possible treatment option. © Copyright F Rocco et al., 2011.

Cite

CITATION STYLE

APA

Chaigneau, L., Kalbacher, E., Thiery-Vuillemin, A., Fagnoni-Legat, C., Isambert, N., Aherfi, L., … Pivot, X. (2011). Efficacy of trabectedin in metastatic solitary fibrous tumor. Rare Tumors, 3(3), 92–94. https://doi.org/10.4081/rt.2011.e29

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free